Lonza invests ￡16 million to further develop the flexibility and capability of its Slough, UK biopharmaceutical manufacturing facility to respond to a broader range of customer projects and strengthen its global network of biologics development and manufacturing. The project is scheduled for completion by the end of 2012. Lonza plans to invest CHF 24 million to expand cytotoxic manufacturing capabilities in Visp, Switzerland to serve growing oncology API market. Cytotoxic APIs are commonly us...